Supplement AERs Require Less Forgiving Risk/Benefit Calculation - FDA
This article was originally published in The Tan Sheet
FDA applies a lower tolerance for risk in evaluating serious adverse event reports for dietary supplements than for drug AERs because of the "uncertainty" surrounding supplement products, an agency official says
You may also be interested in...
FDA will continue to take actions against dietary supplement products prompted by a lower tolerance for adverse events than for other types of products, a policy reflected in its request for a recall the Hydroxycut weight-loss product line
Challenges to the risk-benefit analysis FDA applied in banning the use of ephedra will continue following the Supreme Court's May 14 refusal to hear Nutraceutical Corp.'s appeal, according to the firm's attorney and to industry trade groups
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC